Guggenheim starts Personalis with a Buy, cites ‘best-in-class infrastructure’

As previously reported, Guggenheim initiated coverage of Personalis (PSNL) with a Buy rating and $6 price target Personalis has built a best-in-class infrastructure to do comprehensive genomic, proteomic, and immune profiling in tissue and blood for therapy selection and MRD, says the analyst. While “the dreams of becoming a Porsche have faded far into the rearview mirror,” management has reduced risk and is innovative in responsible revenue generation, adds the analyst, who views the company’s products as “having a place on the market.”